Currency In USD
| Previous Close | 5.39 |
| Open | 5.38 |
| Day High | 5.38 |
| Day Low | 5.38 |
| 52-Week High | 16.02 |
| 52-Week Low | 3.18 |
| Volume | 1.42M |
| Average Volume | 262,783 |
| Market Cap | 242.79M |
| PE | -4.34 |
| EPS | -1.24 |
| Moving Average 50 Days | 5.38 |
| Moving Average 200 Days | 7.01 |
| Change | -0.01 |
Data not available
Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335
GlobeNewswire Inc.
Jun 12, 2025 12:00 PM GMT
Stockholders overwhelmingly approved liquidation and dissolution of the Company at the June 5, 2025 Annual Meeting Initial distribution currently expected in the range between approximately $5.30 and $5.35 per share of common stock, expected in the t
Third Harmonic Bio Announces Plan of Liquidation and Dissolution
GlobeNewswire Inc.
Apr 14, 2025 10:45 AM GMT
Board of Directors has approved plan to liquidate and intends to seek stockholder approval for dissolution of the Company at the Annual Meeting of Stockholders on June 5, 2025 Initial distribution expected in the range between approximately $246.6 mi
Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire Inc.
Mar 27, 2025 12:10 PM GMT
Recently presented THB335 Phase 1 data support advancement into Phase 2 clinical trial in chronic spontaneous urticaria (CSU) Strategic alternatives process underway to maximize value creation across all assets in the company Strong financial positio